Thomas R. Fleming

MathematicsEconomics, Econometrics and FinanceDecision Sciences

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 12 papers. Top paper: “Achieving effective informed oversight by DMCs in COVID clinical trials”.

Achieving effective informed oversight by DMCs in COVID clinical trials

Journal of Clinical Epidemiology(2020)10.1016/j.jclinepi.2020.07.001

N/A

0DataRank · unranked

15 citations

Thomas R. Fleming, David L. DeMets

Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials

medRxiv(2020)10.1101/2020.12.14.20248137

N/A

0DataRank · unranked

25 citations

Jonathan Fintzi, Michael P. Fay, Holly Janes, Lindsey R. Baden, Hana M. El Sahly +25 more

An introduction to the Marburg virus vaccine consortium, MARVAC

PLoS Pathogens(2022)10.1371/journal.ppat.1010805

N/A

0DataRank · unranked

54 citations

Ira M. Longini, Stephan Becker, Karin Bok, David Boucher, Miles W. Carroll +40 more

FDA/Arthritis Foundation osteoarthritis drug development workshop recap: Assessment of long-term benefit

Seminars in Arthritis and Rheumatism(2022)10.1016/j.semarthrit.2022.152070

N/A

0DataRank · unranked

29 citations

Silvana Borges, Daniel J. Clauw, Philip G. Conaghan, David T. Felson, Thomas R. Fleming +19 more

Reliably Assessing Duration of Protection for Coronavirus Disease 2019 Vaccines

The Journal of Infectious Diseases(2022)10.1093/infdis/jiac139

N/A

0DataRank · unranked

5 citations

Donglin Zeng, Yu Gu, Philip R. Krause, Thomas R. Fleming, Dan-Yu Lin

Finding the (biomarker-defined) subgroup of patients who benefit from a novel therapy: No time for a game of hide and seek

Clinical Trials(2023)10.1177/17407745231169692

N/A

0DataRank · unranked

7 citations

Mark D. Rothmann, Thomas R. Fleming, Lisa M. McShane

Monitoring overall survival in pivotal trials in indolent cancers

arXiv (Cornell University)(2023)10.48550/arxiv.2310.20658

N/A

0DataRank · unranked

1 citations

Lisa V. Hampson, Bharani Bharani-Dharan, Frank Bretz, Arunava Chakravartty, Thibaud Coroller +5 more

A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated

UNC Libraries(2023)10.17615/wz35-3h79

N/A

0DataRank · unranked

0 citations

Michael P. Fay, Dean Follmann, Deborah Donnell, James G. Kublin, Myron S. Cohen +24 more

Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on ‘Feels, Functions, Survives’. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency

American Journal of Respiratory and Critical Care Medicine(2024)10.1164/rccm.202312-2213so

N/A

0DataRank · unranked

82 citations

Marya Ghazipura, Thomas R. Fleming, Kerri I. Aronson, Juergen Behr, Kevin M. Brown +33 more

Monitoring Overall Survival in Pivotal Trials in Indolent Cancers

Statistics in Biopharmaceutical Research(2024)10.1080/19466315.2024.2365648

N/A

0DataRank · unranked

13 citations

Lisa V. Hampson, Bharani Dharan, Frank Bretz, Arunava Chakravartty, Thibaud Coroller +5 more

A Perspective on the Appropriate Implementation of ICH E9(R1) Addendum Strategies for Handling Intercurrent Events

Statistics in Medicine(2025)10.1002/sim.70104

N/A

0DataRank · unranked

11 citations

Kevin J. Carroll, Janet Wittes, Scott S. Emerson, Mark D. Rothmann, Sylva H. Collins +2 more

Salvaging information from paused or stopped clinical studies

Clinical Trials(2025)10.1177/17407745251353429

N/A

0DataRank · unranked

1 citations

Thomas R. Fleming, Sara Gianella, Elizabeth Halloran, Sharon L. Hillier, Ira M. Longini +3 more